Every 8-K that Averin Cap Acquisition Corp (ACAAU) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow ACAAU and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ACAAU filings page.
Averin Capital Acquisition Corp. appointed Akiko Moni Miyashita to its board of directors, effective May 28, 2026. She will serve in the first class of directors, with a term ending at the company’s first annual general meeting.
Miyashita, age 70, is the Founder of Beacon Hill Strategy Group since October 2024 and has more than 25 years of experience in strategy, finance and corporate development across healthcare, life sciences, technology and global markets. Her prior roles include Executive Vice President and Chief Strategy Officer at Valo Health, Senior Advisor at McKinsey & Company, Partner at Innosight, and Vice President of Corporate Development at IBM.
In connection with her appointment, she joined an existing letter agreement and a registration rights agreement, agreeing to waive certain redemption rights, vote her ordinary shares in favor of an initial business combination, and receive registration rights for any company shares she owns. She also entered into a standard director indemnity agreement with Averin Capital Acquisition Corp.
Averin Capital Acquisition Corp., a blank check company listed on Nasdaq, announced that holders of its IPO units can begin separately trading the underlying securities on April 10, 2026. Each unit consists of one Class A ordinary share with a par value of $0.0001 and one-sixth of a redeemable warrant.
The Class A ordinary shares will trade under the symbol ACAA and the whole warrants under ACAAW, while any units that remain bundled will continue to trade as ACAAU. Each whole warrant allows the purchase of one Class A ordinary share at an exercise price of $11.50 per share.
Averin Capital Acquisition Corp., a Cayman Islands-based special purpose acquisition company, completed a partial exercise of the underwriters’ over-allotment option tied to its recent IPO. The underwriters purchased an additional 3,386,008 units at $10.00 per unit, adding $33,860,080 in gross proceeds.
The IPO originally sold 25,000,000 units at $10.00 per unit, and a concurrent private placement of 200,000 units to the sponsor added $2,000,000. In total, 28,386,008 public units and 200,000 private placement units have been sold for aggregate gross proceeds of $283,860,080, all largely held in a U.S. trust account. Each unit includes one Class A ordinary share and one-sixth of a redeemable warrant exercisable at $11.50 per share.
Averin Capital Acquisition Corp. completed its initial public offering of 25,000,000 units at $10.00 per unit, raising gross proceeds of $250,000,000. Each unit includes one Class A ordinary share and one-sixth of a redeemable warrant exercisable at $11.50 per share.
The company also sold 200,000 private placement units to its sponsor for $2,000,000, and a total of $250,000,000 was deposited into a U.S. trust account. An additional 3,750,000 units may be sold under an over-allotment option. Public shareholders will have redemption rights in connection with a future business combination.
The independent auditor issued an unqualified opinion on the balance sheet as of February 20, 2026, but highlighted that ongoing costs and the need to complete a business combination raise substantial doubt about Averin Capital’s ability to continue as a going concern.
Averin Capital Acquisition Corp., a Cayman Islands blank check company, completed its initial public offering of 25,000,000 units at $10.00 per unit, generating gross proceeds of $250,000,000. Each unit includes one Class A ordinary share and one-sixth of one redeemable warrant exercisable at $11.50 per share, and the underwriter has a 45-day option to buy up to 3,750,000 additional units.
The company also sold 200,000 private placement units to its sponsor at $10.00 per unit, and a total of $250,000,000 from the IPO and private placement was placed in a U.S.-based trust account. These funds will remain in trust until a business combination is completed or public shares are redeemed under the company’s 24‑month deadline and related charter provisions. The board added three directors, formed audit and compensation committees, adopted amended and restated governing documents, and executed key agreements typical for a newly public blank check company focusing on technology and health industry targets.